Csk-话题@MedSci

#Csk#

97篇内容 | 1202人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1777290, encodeId=1cad1e772908a, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, objectType=article, longId=190422, objectId=cfc8190422fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc8190422fa, replyNumber=0, likeNumber=33, createdTime=2020-05-21, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc8190422fa, moduleTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfc8190422fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777287, encodeId=fa5f1e77287ed, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市, objectType=article, longId=185939, objectId=005818593917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=005818593917, replyNumber=0, likeNumber=40, createdTime=2020-08-20, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=005818593917, moduleTitle=诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005818593917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777291, encodeId=9caa1e7729131, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Circulation: PCSK9抑制剂还能抗栓！, objectType=article, longId=191429, objectId=921319142976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=921319142976, replyNumber=0, likeNumber=32, createdTime=2020-11-28, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=921319142976, moduleTitle=Circulation: PCSK9抑制剂还能抗栓！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=921319142976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777285, encodeId=9fd51e772853c, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂, objectType=article, longId=184019, objectId=daf618401931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daf618401931, replyNumber=0, likeNumber=29, createdTime=2020-01-12, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daf618401931, moduleTitle=诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daf618401931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777293, encodeId=c94b1e7729373, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响, objectType=article, longId=195335, objectId=8002195335e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8002195335e0, replyNumber=0, likeNumber=31, createdTime=2021-05-16, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8002195335e0, moduleTitle=Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8002195335e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777283, encodeId=2b5f1e772839c, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Clinica Chimica Acta：患有代谢综合征的绝经后妇女的循环PCSK9浓度出现增加?, objectType=article, longId=179435, objectId=99741e9435ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99741e9435ba, replyNumber=0, likeNumber=26, createdTime=2020-01-11, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99741e9435ba, moduleTitle=Clinica Chimica Acta：患有代谢综合征的绝经后妇女的循环PCSK9浓度出现增加?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99741e9435ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777289, encodeId=a9731e77289cf, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Blood：酪氨酸激酶Chk、Csk和磷酸酶PTPRJ相互作用调控血小板数量, objectType=article, longId=187702, objectId=8fe718e7025d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fe718e7025d, replyNumber=0, likeNumber=34, createdTime=2020-07-02, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fe718e7025d, moduleTitle=Blood：酪氨酸激酶Chk、Csk和磷酸酶PTPRJ相互作用调控血小板数量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fe718e7025d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777286, encodeId=b4301e77286c1, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响, objectType=article, longId=185077, objectId=c42a1850e7c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c42a1850e7c0, replyNumber=0, likeNumber=36, createdTime=2020-01-04, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c42a1850e7c0, moduleTitle=Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c42a1850e7c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777276, encodeId=47d51e7727628, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新, objectType=article, longId=160533, objectId=43881605336e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43881605336e, replyNumber=0, likeNumber=40, createdTime=2019-07-29, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43881605336e, moduleTitle=临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43881605336e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777281, encodeId=2a811e77281b8, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JACC：PCSK9基因突变引起的低LDL与更低的心血管死亡风险相关, objectType=article, longId=172191, objectId=afd31e21917b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afd31e21917b, replyNumber=0, likeNumber=42, createdTime=2019-11-24, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afd31e21917b, moduleTitle=JACC：PCSK9基因突变引起的低LDL与更低的心血管死亡风险相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afd31e21917b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777284, encodeId=d1461e77284f7, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择, objectType=article, longId=180194, objectId=6961180194ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6961180194ec, replyNumber=0, likeNumber=33, createdTime=2020-07-04, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6961180194ec, moduleTitle=Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6961180194ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777282, encodeId=1b451e77282be, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, objectType=article, longId=178240, objectId=d4021e824003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4021e824003, replyNumber=0, likeNumber=42, createdTime=2020-06-22, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4021e824003, moduleTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4021e824003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777279, encodeId=1bef1e77279f7, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Neurology:“坏胆固醇LDL-C越低越好”受质疑，挑战PCSK9抑制剂安全性：Neurology杂志研究称，<70mg/dl脑出血风险增倍, objectType=article, longId=164741, objectId=43c5164e41c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43c5164e41c4, replyNumber=0, likeNumber=40, createdTime=2019-06-04, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43c5164e41c4, moduleTitle=Neurology:“坏胆固醇LDL-C越低越好”受质疑，挑战PCSK9抑制剂安全性：Neurology杂志研究称，<70mg/dl脑出血风险增倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43c5164e41c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777274, encodeId=2f681e772744e, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=PCSK9抑制剂5年数据，OSLER-1研究最终报告公布！, objectType=article, longId=153515, objectId=544115351578, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=544115351578, replyNumber=0, likeNumber=46, createdTime=2018-12-15, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=544115351578, moduleTitle=PCSK9抑制剂5年数据，OSLER-1研究最终报告公布！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=544115351578)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777269, encodeId=4c9c1e77269e4, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=Pharmacoeconomics：PCSK9抑制剂具成本效果吗？, objectType=article, longId=151158, objectId=8d97151158a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d97151158a5, replyNumber=0, likeNumber=29, createdTime=2019-03-11, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d97151158a5, moduleTitle=Pharmacoeconomics：PCSK9抑制剂具成本效果吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d97151158a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777270, encodeId=2d7d1e772704b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JAHA：PCSK9i在动脉粥样硬化性心血管疾病患者中的使用, objectType=article, longId=152920, objectId=b9741529202c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9741529202c, replyNumber=0, likeNumber=23, createdTime=2019-05-17, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9741529202c, moduleTitle=JAHA：PCSK9i在动脉粥样硬化性心血管疾病患者中的使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9741529202c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777280, encodeId=f5b51e772801c, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JACC：PCSK9抑制剂对慢性肾脏疾病的影响, objectType=article, longId=169024, objectId=3826169024c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3826169024c3, replyNumber=0, likeNumber=34, createdTime=2020-04-05, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3826169024c3, moduleTitle=JACC：PCSK9抑制剂对慢性肾脏疾病的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3826169024c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777278, encodeId=9f701e77278ff, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究, objectType=article, longId=163568, objectId=c531163568f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c531163568f7, replyNumber=0, likeNumber=37, createdTime=2019-09-28, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c531163568f7, moduleTitle=DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c531163568f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777265, encodeId=24361e772652f, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=中国PCSK9抑制剂瑞百安获批安进为HoFH患者提供创新治疗方案, objectType=article, longId=146337, objectId=ea6914633ee6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea6914633ee6, replyNumber=0, likeNumber=33, createdTime=2019-06-24, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea6914633ee6, moduleTitle=中国PCSK9抑制剂瑞百安获批安进为HoFH患者提供创新治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea6914633ee6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1777268, encodeId=3c631e772685b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, objectTitle=JAHA：HIV患者血清PCSK9水平与冠脉内皮功能呈负相关, objectType=article, longId=150171, objectId=f0181501e171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0181501e171, replyNumber=0, likeNumber=40, createdTime=2019-02-07, rootId=0, userName=FukaiBao, userId=979839152460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0181501e171, moduleTitle=JAHA：HIV患者血清PCSK9水平与冠脉内皮功能呈负相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0181501e171)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Csk

2020-05-29

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著

2020-05-21

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市

2020-08-20

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Circulation: PCSK9抑制剂还能抗栓！

2020-11-28

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂

2020-01-12

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响

2021-05-16

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Clinica Chimica Acta：患有代谢综合征的绝经后妇女的循环PCSK9浓度出现增加?

2020-01-11

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Blood：酪氨酸激酶Chk、Csk和磷酸酶PTPRJ相互作用调控血小板数量

2020-07-02

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响

2020-01-04

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新

2019-07-29

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JACC：PCSK9基因突变引起的低LDL与更低的心血管死亡风险相关

2019-11-24

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择

2020-07-04

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标

2020-06-22

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Neurology:“坏胆固醇LDL-C越低越好”受质疑，挑战PCSK9抑制剂安全性：Neurology杂志研究称，<70mg/dl脑出血风险增倍

2019-06-04

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

PCSK9抑制剂5年数据，OSLER-1研究最终报告公布！

2018-12-15

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

Pharmacoeconomics：PCSK9抑制剂具成本效果吗？

2019-03-11

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JAHA：PCSK9i在动脉粥样硬化性心血管疾病患者中的使用

2019-05-17

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JACC：PCSK9抑制剂对慢性肾脏疾病的影响

2020-04-05

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究

2019-09-28

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

中国PCSK9抑制剂瑞百安获批安进为HoFH患者提供创新治疗方案

2019-06-24

FukaiBao (审核中...)

前往app查看评论内容

#Csk#

JAHA：HIV患者血清PCSK9水平与冠脉内皮功能呈负相关

2019-02-07

科室
- - 订阅+
  - 更多科室
工具
服务